Member Info for Wigwammer

Bermuda, so the underlying message in the research is from Scancell and that involves applying standard percentages. But then the clear message to everyone here from Scancell is that the data is not standard but unprecedented. So which message accurately reflects their view?

Thanks for your thoughts, bermuda. But why would you apply standard percentages when the highly informed CEO/CSO has described the preclinical data as unprecedented? … “the likelihood of success percentages are standard for the stage of development”

Surely they anticipate the covidity data will be good, to be making the following read across, right near the start of yesterdays RNS? I don’t see any material change of position - someone else may want to take it forward… “Recruitment completed in COVIDITY Phase 1 clinical trial in South Africa, with safety and immunogenicity data expected in Q1 2023, providing read across to our second-generation ImmunoBody(R) platform.”

I agree testudo. Carclo operate in a growing market, and with debt and pension payments well covered by current free cash flow all that growth will fall into the laps of shareholders. Settlement relating to the cancelled contract should also improve sentiment. GLA

Fantastic risk/reward here IMO. Have fully loaded back to level when it was sub 6p a few years back. Top line growing, experienced management in place, low cyclicality sales with large medtechs… once margins normalise at target 8-9%, all of the residual profit post pension/interest payments will fall in shareholders laps.. GLA :)

Perhaps bioNTech are simply putting a flag in the earth because they know quite shortly the attention may be going elsewhere. A 15+ cancer centre trial in the nhs is likely to be taken seriously by patients, practitioners, pharmaceutical providers, pharmaceutical marketing, and ultimately government. I guess you are going to be particularly keen to get that flag in the earth if you suspect the result of said trial is going to be positive!

In fairness, we do not know yet that the U.K. government is not going to support Scancell. While I very much hope moditope works with the majority of patients, there is still likely to be a material role for individualised medication. It may well be the government plans to support both (but we need data first!)

AGM was November, not October.. apologies.

LD at AGM asked are Biontech still interested in TCR?… “yes they are still interested, yes we can harvest them, we are doing this as we speak… they are even more interested in the vaccine though because that is a simpler and cheaper way forward”…. Ie as at end October, Biontech interested in multiple aspects of SCLP’s pipeline.

…though my impression from the AGM was they had more positive news which they felt unable to talk about. Wait and see is all we can do. ATB

Well I think it’s sensible to ask why no update yet? They will likely have at least the first scans from all 3 patients, and if they had seen another one or two partial responses I see little reason why they wouldn’t have RNS’d it. Perhaps we need to moderate some of the most optimistic expectations, though I hope not.

I don’t think scampthedog’s post makes much sense. If one had shorted at 27p as he suggests and closed today you would have made 13%. At the same time he concedes an RNS pointing to a “very very bright future”
could drop any day… 13% = a bwollox return for the risk taken, not surprised people were sceptical, IMO.

RP - last paragraph spot on, good point.

I think it’s mixed, WTP. But happy to be shown otherwise. If you are trying to demonstrate safety, would make sense to include a range of different cancers. But if you were covering 3 cancer types in cohort 2, and anticipate trial practitioners know efficacy before the market is told, then you may expect to see spiked interest in one or two types - the ovarian cohort is nearly full already.

My understanding is that it is heard to treat, and there are no approved PD1 treatments available. But my point is - what is driving the outlying level of internet here? If one of the cohort 2 patients is ovarian and known to be responding well, it might explain a lot.

One of the outstanding revelations at the AGM was the “superb” uptake in the Ovarian monotherapy cohort. If one of the other two cohort 2 patients is ovarian, you wouldn’t have to be Clueso to work out what may be driving the enthusiasm. GLA

Well, just to add my tuppence, they never confirmed the observation. “ This early observation requires further confirmation with subsequent scans”. So without a further RNS, they have not confirmed any response.

Isn’t the information material and non public? Presumably any patient has to sign non disclosure before going on a trial like this. The process in October was that Scancell updated the market and the posts arrived a few days later ie the information had already been made public. So similar here - the patient and Scancell are informed, Scancell decide whether to go public, if they do then the patient is free to post once the information is disseminated. I certainly wouldn’t expect an RNS on Monday though - it would be daft for Scancell to go public prior to the patient being informed.

Fantastic news for patients and scancell, imo. To quote LD at the AGM - ?We do not have an approved cancer vaccine out there, so there is a lot of cynicism that cancer vaccines can actually work?? I suspect that cynicism is rapidly vanishing, and those companies that passed on Scancell the first time will be having another think.

Yes, good point WF!
RP - according to LD, no one….. “ We’ve had to go longer and deeper but when we get there it will be a bigger story because we will have achieved what nobody else has achieved…”